← Back to Search

Procedure

Live Donor Liver Transplantation for Colorectal Cancer Liver Metastases

N/A
Recruiting
Led By Gonzalo Sapisochin, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The patient has undergone systemic chemotherapy (eg. FOLFOX +/- bevacizumab or FOLFIRI +/- bevacizumab) for ≥3 months
Bilateral and non-resectable LM
Must not have
Renal dysfunction with an estimated creatinine clearance of less than 50 ml/min
Patients with debilitating neuropathy (CTCAE > grade 2)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-, 3- and 5 years
Awards & highlights

Summary

This trial will offer live donor liver transplantation to select patients with unresectable metastases that are 1) limited to the liver and 2) stable (non-progressing) on standard chemotherapy.

Who is the study for?
This trial is for Canadian residents with colorectal cancer that has spread to the liver and can't be removed by surgery. Participants need a willing, compatible living donor for liver transplant, stable or improving cancer markers on chemotherapy, and good physical function (ECOG score 0-1). Pregnant women and those not using birth control are excluded.
What is being tested?
The study tests live donor liver transplantation in patients whose colorectal cancer has spread only to the liver and isn't getting worse on standard chemo. It compares survival rates of these patients post-transplant against those who leave the study before receiving a transplant.
What are the potential side effects?
Potential side effects include complications from major surgery like bleeding, infection, rejection of the new liver, anesthesia risks, and immunosuppression-related issues such as increased risk of infections or other cancers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been treated with chemotherapy for at least 3 months.
Select...
My liver metastases cannot be surgically removed and are in both lobes.
Select...
My cancer has only spread to my liver and hasn't invaded major blood vessels.
Select...
My colorectal cancer has not grown beyond the outer layer of the colon.
Select...
My colorectal cancer has spread to my liver.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidneys are not working well, with a low creatinine clearance rate.
Select...
I do not have severe nerve pain or damage.
Select...
I have a history of HIV or chronic hepatitis B/C.
Select...
My tumor is BRAF positive.
Select...
I have trouble breathing or lung problems.
Select...
I have had surgery to remove part of my lung.
Select...
My liver metastasis progressed before my transplant surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-, 3- and 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-, 3- and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
self-reported quality of life as assessed by EORTC QLQ-C30 questionnaire
survival of intervention vs standard treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: transplantationExperimental Treatment1 Intervention
Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,514 Previous Clinical Trials
500,185 Total Patients Enrolled
Gonzalo Sapisochin, MDPrincipal InvestigatorUniversity Health Network, Toronto
5 Previous Clinical Trials
208 Total Patients Enrolled

Media Library

Live Donor Liver Transplantation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT02864485 — N/A
Colorectal Cancer Research Study Groups: transplantation
Colorectal Cancer Clinical Trial 2023: Live Donor Liver Transplantation Highlights & Side Effects. Trial Name: NCT02864485 — N/A
Live Donor Liver Transplantation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02864485 — N/A
~3 spots leftby Dec 2025